Dynavax Technolo Stock Price, News & Analysis

Dynavax Technologies Corporation (Nasdaq: DVAX) will release its first quarter 2021 financial results on May 6, 2021, after market close. A conference call and audio webcast will follow at 4:30 p.m. ET. The company focuses on developing vaccines, with its first product, HEPLISAV-B®, already approved in the U.S. and EU for hepatitis B prevention in adults. Dynavax continues to advance its CpG 1018 adjuvant through collaborations for COVID-19, pertussis, and universal influenza vaccines.

Dynavax Technologies Corporation (Nasdaq: DVAX) announces that Valneva SE has initiated a pivotal Phase 3 clinical trial for its COVID-19 vaccine candidate VLA2001, utilizing Dynavax's CpG 1018 adjuvant. The Cov-Compare trial aims to compare VLA2001 against AstraZeneca's Vaxzevria in a study involving 4,000 adults, focusing on the superior neutralizing antibody response. Following promising Phase 1/2 results, Valneva plans regulatory submission in autumn 2021 if Phase 3 results are favorable, marking a significant step in COVID-19 vaccine development.

Dynavax Technologies Corporation (Nasdaq: DVAX) announced that two abstracts related to its hepatitis B vaccine, HEPLISAV-B, will be presented at the 2021 Annual Conference on Vaccinology Research (ACVR) scheduled for April 26-27, 2021. The first abstract evaluates the safety and immunogenicity of HEPLISAV-B in adults undergoing hemodialysis, while the second presents findings on the occurrence of acute myocardial infarction in over 60,000 patients vaccinated with HEPLISAV-B compared to another vaccine. These presentations can be viewed on-demand until June 30, 2021.

Dynavax Technologies Corporation (Nasdaq: DVAX) announced positive results from Valneva's Phase 1/2 trial of its COVID-19 vaccine candidate, VLA2001, featuring Dynavax's CpG 1018 adjuvant. The trial involved 153 healthy adults aged 18 to 55, showing a 100% seroconversion rate for S-protein binding IgG in the high dose group. Valneva aims to start a pivotal Phase 3 trial by the end of April 2021, pending regulatory approval. VLA2001 is designed to prevent COVID-19 and may be modified for new variants.

Dynavax Technologies (Nasdaq: DVAX) announced the grant of nonstatutory stock options to purchase 142,000 shares to six new hires. The options, granted on April 1, 2021, have an exercise price of $9.73 per share, equaling the stock's closing price on that date. Each option has a 7-year term and vests over three years, tied to continued employment. This action complies with Nasdaq Listing Rule 5635(c)(4) and is part of Dynavax's 2021 Inducement Award Plan, aimed at attracting talent in the biopharmaceutical sector.

Clover Biopharmaceuticals and Dynavax Technologies announced the dosing of the first participants in the global Phase 2/3 SPECTRA trial, evaluating Clover's S-Trimer COVID-19 vaccine candidate. This double-blind, randomized study aims to assess the vaccine's efficacy, safety, and immunogenicity in over 22,000 adults across multiple continents. An interim analysis is expected in mid-2021. The trial is fully funded by the Coalition for Epidemic Preparedness Innovations, with hopes of producing hundreds of millions of doses for global distribution, emphasizing the vaccine's stability and manufacturing potential.

Dynavax Technologies Corporation (Nasdaq: DVAX) will present at the H.C. Wainwright Virtual 2021 Global Life Sciences Conference on March 9-10, 2021. CEO Ryan Spencer will lead the presentation, which will be available on demand starting at 7:00 a.m. E.T. on March 9, accessible via the Investors section of the company’s website. Dynavax specializes in developing vaccines, having commercialized HEPLISAV-B®, a hepatitis B vaccine, and is advancing CpG 1018 as a vaccine adjuvant for various collaborations.

Dynavax Technologies Corporation (Nasdaq: DVAX) announced the grant of stock options totaling 350,000 shares to its newly appointed Senior Vice President and Chief Financial Officer, Ms. MacDonald, effective March 1, 2021. Additionally, the company issued 74,300 shares in stock options to four newly hired employees. These options have a 7-year term, vesting over three years, with an exercise price of $8.90, reflecting the closing price on the grant date. This move complies with Nasdaq Listing Rule 5635(c)(4) and is aimed at attracting talent amidst ongoing vaccine developments.

Dynavax Technologies (DVAX) reported its financial results for Q4 and full year 2020, highlighting a net loss of $15.5 million in Q4, improved from a loss of $36.8 million in Q4 2019. Total revenues rose to $46.6 million for 2020, up from $35.2 million in 2019. HEPLISAV-B product revenue reached $36 million, a 4% increase year-over-year. The company anticipates significant revenue from collaborations utilizing its adjuvant CpG 1018, potentially generating up to $230 million in 2021. Cash reserves stood at $165 million at the end of 2020.